The drug is called NU-9, and a team from Northwestern University in the US tested it on mouse models of Alzheimer's disease.

Clinical trials for drug development are notoriously slow and expensive, and only a small fraction of drug candidates end up being approved by the regulatory authorities. The extensive bottlenecks in ...

Designing an efficient platform is crucial for any industrial process. This design process is known as process development, and it has become increasingly important in the pharmaceutical industry at ...

The weight-loss drug market is booming, with biotech firms racing to secure their place in a lucrative sector currently ...

Insmed said on Wednesday it had discontinued the development of its experimental anti-inflammatory drug to treat a chronic sinus condition after it failed to show benefit in a mid-stage study, sending ...

For some common medical conditions, timing is everything when it comes to taking medications. Now, a customizable capsule engineered at UC San Diego could simplify complicated dosing schedules thanks ...

Discover how drugs prevent, cure, and alleviate ailments. Learn about over-the-counter vs. prescription drugs and the ...

Researchers have developed a new antimalarial drug candidate designed to address the growing challenge of drug resistance and ...

The loss of domvanalimab is the latest in a string of high-profile failures recorded across the biopharma world for the TIGIT ...

Starton Holdings plans $40M IPO for cancer drug delivery innovations, but weak IP and limited backing make this a potentially ...